Shandong Xinhua Pharmaceutical's (HKG:0719, SHE:000756) marketing application for pentazocine has been approved by China's National Medical Products Administration, a Monday bourse filing said.
Pentazocine, which was developed by Sterling Winslip, now Sanofi, in the US and has been registered and China and abroad, is a kind of refined hemp drug use for pain relief, including cancer, traumatic, and postoperative pain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments